The Cell Therapy Laboratory technologists are trained in sterile techniques in order to assist with both autologous and allogeneic bone marrow harvest procedures.
The Cell Therapy Laboratory technologists have been trained in sterile techniques and have the ability to assist the transplant physician in the operating room during adult or pediatric, autologous or allogeneic bone marrow harvest procedures.
Cell Therapy Laboratory staff is available for each procedure, if scheduled in advance. Cell Therapy lab technologists help prepare an appropriate volume of bone marrow harvest media and deliver media to the operating room. The bone marrow harvest media includes 100 mL of Plasma-Lyte A pH 7.4 and 10,000 units of preservative free heparin for every 1,000 mL of bone marrow harvested. Technologists provide a sterile commercially available container for collected marrow. During the procedure technologists monitor volume of harvested marrow, and irrigate collection syringes with heparinized media.
In the operating room, technologists will filter marrow using a series of decreasing size inline filters (850, 500 and 200 micron). Product will be labeled according to established regulatory requirements. Technologists will transport the product to the processing laboratory or the transplant floor if direct infusion is ordered.
A Carter BloodCare Cell Therapy Laboratory technologist will personally deliver all locally requested frozen HPCs to the recipient’s bedside at the time of transplantation. Frozen cells are transported at -150°C or colder using a liquid nitrogen dry shipper.
On the day of transplant the technologist reports to the recipient’s bedside with the frozen graft, a preheated 37°C waterbath, and a lab cart stocked with all the necessary supplies required for a bedside thawing and infusion. Each HPC product is compared with the physician’s order to ensure proper patient identification. Bags are thawed one at a time at the patient’s bedside using gentle agitation in the 37°C waterbath.
Once a product is thawed, a sterile bag spike is inserted into one bag entry port and a blood component recipient set containing an inline 170 micron or larger filter is inserted into the remaining entry port. The product is then issued to the infusionist. Once the cells have been checked for proper identification according to hospital policy they may be infused.
Use of a leukoreduction or microaggregate filter and irradiation of any HPC product is strictly prohibited.